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Abstract: Several congenital and acquired conditions may result in severe narrowing of the urethra
in men, which represent an ongoing surgical challenge and a significant burden on both health and
quality of life. In the field of urethral reconstruction, tissue engineering has emerged as a promising
alternative to overcome some of the limitations associated with autologous tissue grafts. In this
direction, preclinical as well as clinical studies, have shown that degradable scaffolds are able to
restore the normal urethral architecture, supporting neo-vascularization and stratification of the
tissue. While a wide variety of degradable biomaterials are under scrutiny, such as decellularized
matrices, natural, and synthetic polymers, the search for scaffold materials that could fulfill the
clinical performance requirements continues. In this article, we discuss the design requirements
of the scaffold that appear to be crucial to better resemble the structural, physical, and biological
properties of the native urethra and are expected to support an adequate recovery of the urethral
function. In this context, we review the biological performance of the degradable polymers currently
applied for urethral reconstruction and outline the perspectives on novel functional polymers, which
could find application in the design of customized urethral constructs.
Keywords: urethral strictures; urethral tissue engineering; biodegradable polymers; acellular matrix;
smart polymers
1. Introduction
The male urethra can be affected by several primary, as well as secondary conditions, including
hypospadias, fistulas, trauma, and malignancy [1]. In children, hypospadias is a common congenital
malformation of the external genitalia, where shortage of the urethra is a major concern [2].
This disorder occurs in about 1 out of every 200 live male births and its surgical management
remains challenging, especially in the severe forms where the patients suffer from post-operative
complications [3,4]. In adult males, urethral injuries can take place at any part of the urethra distal to
the bladder neck, as the result of different pathologies, including inflammatory, traumatic, or iatrogenic,
with an incidence of 5000 new cases annually in the USA alone [5,6]. While male urethral conditions
represent a significant medical and surgical burden, female urethral disorders are less demanding due
to different etiology and anatomical constraints. Thus, management of female urethral disorders will
remain outside the scope of the current review.
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Overall, disorders of the male urethra may lead to a breach of the continuity of the urethral
mucosa, which results in extravasation of urine, with the possibility of subsequent inflammation
and, ultimately, stricture formation. The surgical management of urethral strictures differs according
to the severity and length of the affected segment. While the basic approach for short segmental
defects comprises resection and end-to-end anastomosis, long defects require open urethroplasty
using autologous tissue grafts. Buccal mucosa is currently the most widely used graft material for
urethroplasty [7–9]. However, limited amount of autologous tissue and donor site morbidity remain
as clinical obstacles. Patients undergoing buccal tissue harvest are at risk of suffering scarring and
contracture at the donor site, persistent pain, numbness, or parotid duct injury. The overall rate of oral
complications has been shown to be between 3% to 4% [10]. Furthermore, buccal grafts are associated
with higher costs of urethroplasty and a longer hospital stay [11].
Urethral tissue engineering has recently emerged as a viable alternative to overcome the issues
associated with autologous grafts [12]. In addition to eliminating the need of harvesting autologous
tissue, tissue engineered solutions are expected to become “off-the-shelf” products in the future [13].
Tissue engineering may involve scaffolds alone, which exploit the body’s natural regeneration
ability, or cell-seeded scaffolds, which are used as a graft substitute. In any case, urethral tissue
engineering approaches rely on biodegradable scaffold materials, which aim to recapitulate the
structural, mechanical, and biological properties of the native urethra, to ultimately restore normal
urethral functionality. For instance, it is desirable to provide proper mechanical compliance, to allow
elastic deformation during erection of the penis, and barrier function to avoid urine leakage to the
underlying tissues [14,15].
The aim of this article is to present the rationale for different designs for urethral replacement,
as well as the limitations of each design choice. Given the inability of grafts and non-degradable
polymers to meet the clinical performance requirements, this review will focus on the ability of
degradable polymeric scaffolds to mimic the native urethral structure, in an effort to restore complete
urethral function. Toward this purpose, we initially describe the properties of the male urethra that
dictate design requirements for a completely regenerated structure. Then, we review the preclinical
and clinical results obtained with current biodegradable biomaterials, discussing their advantages
and limitations. Finally, we discuss the perspectives on novel functional polymers, which may find
application in the field of urethral tissue engineering.
2. Structural and Functional Properties of the Male Urethra
The male urethra is a distensible tubular structure connecting the urinary bladder to the meatus,
which mainly serves as a conduit to eliminate the urine. As shown in the diagram of Figure 1, the male
urethra can be divided into three segments. The most proximal segment, the prostatic urethra, passes
through the prostate and constitutes the widest portion. The middle segment, the membranous urethra,
is the shortest and is surrounded by the external urethral sphincter. When the sphincter is closed,
the intraluminal pressure on the membranous urethra can reach up to 120 cm H2O. The most distal
and longest portion is the penile urethra, which is surrounded by the corpus spongiosum, a richly
vascularized erectile tissue that provides support to the urethra. Histologically, the urethra is composed
from three different layers: an inner mucosal epithelial lining, a submucosa comprising of fibroblasts,
and a muscular layer (Figure 1). The urothelial lining of the urethra appears to be essentially different
from that of the bladder [16]. This can be observed by change of the epithelium from transitional
(in the bladder), to pseudostratified (in the penile urethra), to stratified squamous at interface with
the skin. The muscular layer is mainly composed of smooth muscle cells. The striated component
extends from the base of the bladder to the membranous urethra, where it forms the external urethral
sphincter for active continence. Each cell layer contains a complex extracellular matrix (ECM) structure,
mainly composed of collagen I and III, glycosaminoglycans (GAGs), and elastin [17,18]. Mechanically,
while collagen gives strength and structural support, elastin provides reversible extensibility [19].
While the detailed histological composition of the urethra has been thoroughly described in female
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animals, which are relevant models for continence research the histology of the male urethra, which
can potentially be translated into urethral tissue engineering studies, has not been sufficiently explored
yet [20–24].Int. J. Mol. Sci. 2018, 19, x 3 of 16 
 
 
Figure 1. Diagram showing the general anatomical features of the human penis with a cross section 
at the level of the penile urethra showing the different anatomical structures. The histological 
examination at the level of the cross section shows the two corpora cavernosa and the urethra with its 
three main layers: epithelia, submucosa and spongiosum (histological images reprinted with 
permission from Ref. [25]). © 2019 Regents of the University of Michigan. 
Apart from its signaling role, to maintain the cellular homeostasis, the ECM plays an essential 
role in defining the mechanical compliance of the urethra, which should be able to dilate its lumen 
during micturition and stretch considerably during erections [26,27]. During urination, the urinary 
bladder’s pressure increases up to 50–60 cm H2O and expels the urine with a flow rate about 20–30 
ml/sec. One of the major points not considered frequently in producing urethral constructs is the 
maintenance of enough compliance of the urethra during micturition, in order to decrease patient 
discomfort and protect the upper urinary tracts. Different studies investigated different variables 
affecting urethral compliance in a clinical background [28–30]. Normal urethral compliance is 
dependent on the optimal passive viscoelastic properties of the urethral wall in order to keep the 
urination process under low pressure so as not to harm the urinary bladder, kidneys, and cause 
infections. Different therapeutic and surgical conditions of the urethra can affect these parameters 
and this was objectively demonstrated through in vivo experiments using different animal models 
[31]. We hypothetically assume that the same effects can occur when implanting tissue-engineered 
urethral constructs, and can be significantly ameliorated with appropriate degradability of the 
scaffold and subsequent healthy tissue regeneration. It is worth noting that differences in 
stiffness/compliance between the implanted segment (and subsequent regrown engineered 
neourethra and adjacent native urethra) determines the range of mechanical mismatch that still 
would not meet the clinical performance requirements. This reflects the inability of the compensatory 
capacity of the normal urethra to the noncompliant/stiff new urethral segment. This can be elicited 
from the clinical/functional perspective, as it is known that even a very short fibrotic segment can 
have as significant clinical burden as long segments. This is clear from the pathological aspects of 
posterior urethral valves in male children, which are the most common reason of renal 
transplantation before puberty. Similar outcomes are commonly observed with urethral strictures in 
adults, in which very short strictures can affect urinary function and represent a risk for renal 
complications [32]. 
Urethral biomechanical parameters (tension–strain relation) can explain the relation between the 
structure and function of the urethra. Studies have shown that the urethra possesses a nonlinear 
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at the level of the cross section shows the two corpora cavernosa and the urethra with its three main
layers: epithelia, submucosa and spongiosum (hist logical images reprinted with p rmission from
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Apart from its ignaling role, to maintain the cellu ar homeostasis, the ECM plays an ess ntial role
in d fi ing the mechanical compliance of the urethra, which s ould be able to dilate its lumen duri g
micturition and stretch considerably during erections [26,27]. During urination, the urinary bladder’s
pressure increases up to 50–60 cm H2O and expels the urine wit a flow rate about 20–30 mL/s. One of
the major points not considered frequently in producing urethral constructs is the maintenance of
enough compliance of the urethra during micturition, in order to decrease patient discomfort and
protect the upper urinary tracts. Different studies investigated different variables affecting urethral
compliance in a clinical background [28–30]. Normal urethral compliance is dependent on the optimal
passive viscoelastic properties of the urethral wall in order to keep the urination process under low
pressure so as not to harm the urinary bladder, kidneys, and cause infections. Different therapeutic and
surgical conditions of the urethra can affect these parameters and this was objectively demonstrated
through in vivo experiments using different animal models [31]. We hypothetically assume that the
same effects can occur when implanting tissue-engineered urethral constructs, and can be significantly
ameliorated with appropriate degradability of the scaffold and subsequent healthy tissue regeneration.
It is worth noting that differences in stiffness/compliance between the implanted segment (and
subsequent regrown engineered neourethra and adjacent native urethra) determines the range of
mechanical mismatch that still would not meet the clinical performance requirements. This reflects the
inability of the compensatory capacity of the normal urethra to the noncompliant/stiff new urethral
segment. This can be elicited from the clinical/functional perspective, as it is known that even a very
short fibrotic segment can have as significant clinical burden as long segments. This is clear from
the pathological aspects of posterior urethral valves in male children, which are the most common
reason of renal transplantation before puberty. Similar outcomes are commonly observed with urethral
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strictures in adults, in which very short strictures can affect urinary function and represent a risk for
renal complications [32].
Urethral biomechanical parameters (tension–strain relation) can explain the relation between
the structure and function of the urethra. Studies have shown that the urethra possesses a nonlinear
cross-sectional area pressure, meaning that the tissue is fairly deformable at low pressure (facilitating
voiding), but less deformable at higher stress levels (protective against over distention) [33]. It has also
been shown that abnormal urethral narrowing or obstruction, as well as post-operative complications
and recurrence of pathology, can be reliably screened by uroflowmeter measurements [33,34].
Uroflowmetry is considered a sensitive noninvasive functional modality for the assessment of the lower
urinary tract dynamics and could be used for better assessment of the functional outcomes. However,
this structure–function relationship has not been sufficiently investigated in previous preclinical
urethral tissue engineering experiments.
Adding to the complexity of the picture, in hypospadias and urethral surgery, additional
biomechanical and clinical problems may arise [34–36]. Another aspect which is not frequently
taken into account, particularly in pediatric patients, is that the urethra doubles its length during
puberty. This should be a main consideration during scaffold synthesis in order to have resulting
healthy tissue that have this extent of growth [37]. Urethral graft contracture often occurs following
prostatectomy, hypospadias repair, cystoscopy, and urethral cauterization. Several tissue engineering
approaches were examined to manage these strictures that included using tissue-engineered buccal
mucosa [38]. Another approach has been exploiting the anti-inflammatory properties of stem cells, such
as human bone marrow-derived mesenchymal stem cells (MSC) combined with CD34+ hematopoietic
stem/progenitor cells [39].
Another important point that has not received too much attention in the design of scaffolds for
urological tissue engineering is the avoidance of urine leak, even when the urine is known to be
highly cytotoxic. In the normal urethra, urothelium barrier function is maintained by three structures:
uroplakin proteins in the apical cell membrane, tight junctions situated between the superficial
umbrella cells, and urothelial GAGs and proteoglycans, covering the umbrella cells [40]. Formation
and regeneration of the urothelium are critical to prevent urethral stricture formation. In addition,
an intact urothelium prevents bladder detrusor muscle over-activity [41], inflammation, and fibrosis.
When the protective uroplakin barrier is dysfunctional, as it is during the early stages of urothelium
regeneration, cytotoxic agents bind spontaneously to the anionic milieu of inner layers of the bladder
mucosa. Thus, deep penetrating urine is believed to exert a significant impact on the viability of
cells within the scaffolds [42]. Since urine has a harmful effect on the cellular components of a tissue
engineered urethra, it is important that the scaffold has adequate impermeability since it might partially
act as an isolation barrier. It is worth noting that leak here is not meant for fluid but for the cytotoxic
components [43]. In urethroplasty, the avoidance of urine leak is supported by catheterization of the
patient within the first week after graft implantation, until healthy regenerated urothelial tissue is able
to provide the adequate barrier function.
3. Polymeric Biomaterials in Urethral Tissue Engineering
Initially, non-degradable materials were assessed for urinary tract reconstruction, but they resulted
into several complications such as calcification, fistulae [44,45], chronic hematuria, stone formation, and
development of significant contractures up to 50% of their initial lengths [46]. While non-degradable
urinary scaffolds have resulted in failure of the growth of seeded cells, the addition of collagen has
resulted in significant cell growth and differentiation [47]. On the other hand, degradable biopolymers
are intended to permit tissue ingrowth, while the scaffold is resorbed over time, in a controlled manner
(Figure 2). Physiological metabolic processes typically remove the degradation byproducts [48]. As a
result, it is important to investigate the biodegradation characteristics of the scaffolds in order to achieve
a successful tissue engineered replacement [49]. The incorporation of cells within the scaffold appears
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to improve the biocompatibility, as the cells contribute to the remodeling process through synthesis of
ECM components, which are essential for the long-term survival of the implanted construct.
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Figure 2. Schematic representation of the advantages of scaffold degradability with regards to
restoration of “healthier” tissue engineered urethral replacement. Non-degradable biocompatible
scaffolds have lead to several undesirable outcomes like shortenig of the implant, calcification, and
narrowing of the urethra, collectively kown as “non-functional remodeling”. On the other hand,
resulting regrown tissues following implantation of optimized degradable constructs has lead to
“constructive remodeling” with the resulting tissues closer to the native normal urethra.
The appropriate synchronization between the biodegradation of the scaffold and cellular
component growth is crucial for the success of a tissue-engineered implant. The scaffold should
tolerate the mechanical forces sustained during handling, suturing, and normal patient activities [50].
Biodegradable scaffolds in general have a variable biodegradation between days to several months.
The timeline to allow proper function and regeneration is one of the most important variables in the
design of degradable tissue engineered constructs. This actually has been explained recently in a
vascular tissue engineering model of constructs, where the in vivo degradation process goes through
consecutive controlled phases [51]. There is an initial “stenting phase” for merely the transfer of
intraluminal fluids with minimum acute recoil, sufficient radial strength, and conformability. This is to
be followed by a “restoration stage” as a result of the return of in-scaffold contractility in response
to physiological (or pharmacological) stimuli, until lastly resorption occurs. Because the mechanical
properties of absorbable scaffolds are designed to change over time, there are distinctive concerns for
bench testing, including pretest acquisition, handling before and through testing, and time-dependent
evaluations. As mentioned above, the first phase of the absorbable urethral scaffolds is to maintain
lumen patency. Therefore, the essential attributes are growth capability, recoil, radial strength, and
fatigue behavior. Throughout the restoration phase, the scaffold transforms from an active support
of the urethra to a passive implant with a discontinuous structure. This transition is monitored by
evaluating the modification in radial strength over time furthermore due to the fatigue behavior.
Degradable polymers for urethral tissue engineering have been typically obtained from natural
sources or by synthesis. Natural biomaterials include acellular matrices obtained from cadaveric or
animal organs via enzymatic, physical, or chemical decellularization methods, or natural polymers,
such as silk fibroin (SF). In general, natural biomaterials possess integrin-binding peptide sequences
and surface topography that can facilitate cellular growth and differentiation, and accelerate the
process of angiogenesis [52]. Synthetic polymers, on the other hand, constitute the biggest subset
biodegradable materials in use today. The most commonly used polymers include linear polyesters,
poly-lactic acid (PLA), poly-glycolic acid (PGA), poly lactic-co-glycolide (PLGA), copolymers, and
polycaprolactone (PCL) [53]. Some of the advantages of synthetic polymers are that they display
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reproducible mechanical characteristics, degrade fast, and are frequently less expensive than biologic
scaffolds. However, these synthetic polymers have limited biocompatibility because they lack specific
molecular elements for interaction with cells and proteins, usually requiring surface treatments to
promote cell attachment [54]. Comprehensive reviews of the different biomaterials used in urethral
tissue engineering are available elsewhere [12,13,55,56]. While these approaches, in general, have a
goal to mimic the properties of the urethra to recover complete function, they have not been able to
achieve this goal. It is, however, worth noting that it might be possible to restore the functionality of
the urethra to an acceptable level without necessarily duplicating its native structure. In the following
section we will focus on the preclinical results obtained using biodegradable scaffolds obtained from
natural sources.
4. In Vivo Performance of Biodegradable Scaffolds for Urethral Reconstruction
Acellular matrices, such as small intestinal submucosa (SIS) and bladder acellular matrix (BAM),
are by far the most frequent scaffold type assessed in vivo for urethral tissue repair [57]. SIS is obtained
from porcine small intestines, where the mucosal, serosal, and muscular layers are mechanically
removed from the inner and outer surfaces of the intestinal wall to leave a 0.1 mm collagen-rich
membrane, mostly formed of the submucosa [58,59]. In vivo animal experiments revealed that, when
used for urethral replacement, SIS permitted rapid cellular growth and significant angiogenesis,
often comparable to skin and mucosal grafts [60–63]. Moreover, SIS biodegrades totally in about
four to eight weeks, and its degradation products are eliminated in the urine [64]. SIS has an extra
benefit over other biomaterials regarding its high tendency to stretch under force and low tendency
to break [65]. SIS showed favorable results when used for corporal body grafting to correct severe
grades of chordee [66,67]. It was also been shown that seeding SIS with appropriate cells brings a
better outcome in a rabbit model of urethroplasty (Figure 3) [68]. It is believed that extended periods
of urinary diversion is important when using SIS for urethral replacement to lower the risk of urine
extravasation and reduce early irritation [69]. Another option is to line it with another material
having higher hydrophobicity in a multilayer manner in order to lower urine leakage. There are a
number of natural material systems that have come close to restoring structure to near the native tissue.
These systems, however, have still not met all the needed design constraints. The next section will
describe some new materials that will help to better restore the original structure and function. Despite
their evident advantages, SIS had less favorable results when used in clinical experiments, with the
infection being the biggest limitation [70,71]. Furthermore, the regenerative potential of SIS depends
on the age of the donor and the area of the intestine from which the SIS matrices are derived. These
limitations have prevented SIS from being considered as an ideal scaffold to aid in effective urethral
tissue engineering [72].
BAM is another example of a decellularized matrix, which has shown to successfully support
regeneration of the urethra in vivo [44,73–76]. Using BAM for urethroplasty in a rabbit model,
implantation of cell-loaded scaffolds demonstrated a normal urethral architecture by four weeks and
the neourethra could be hardly differentiated from native urethra both grossly and histologically after
six months [77]. Chun et al. also showed in his experiments that ventral onlay urethroplasty using an
acellular bladder submucosa matrix (BSM) scaffold combined with an autologous urethral tissue graft
represents a viable option for urethral replacement (Figure 4) [73]. However, residual immunogenic
components have been detected within BAM despite the stringent decellularization process [78], and
further improvement in processing may be necessary for BAM to achieve successful tissue engineering.
Furthermore, decellularized matrices present other limitations such as batch-to-batch variability, and
may cause inflammatory reactions due to residual DNA, RNA, and xeno-antigens, which could lead to
graft rejection and functional failure.
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Figure 3. Histological and immunohistochemical assessment of urethral reconstruction in animals using
cell-loaded, decellularized SIS scaffolds (Cell seeded PAA) showing regrowth of layers of transitional
epithelium, more smooth muscle, and vessels in contrast to the cell loaded but non- ecell larized
(Cell seeded non-PAA) and non-loaded, decellularized scaffolds (Unseeded PAA). Scal bar = 20 µm.
(reproduced with pe mission from [68]). © 2016 Zhang et al.
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autologous urethral tissue graft resulted in a complete epithelialization, compact muscular layers, nd
progre sive infiltration by vessels i the r generated urethra. In contrast, the BSM grafts alone revealed
keratiniz d epithelium, abundant collageno s fibrous connective tissue, and were devoid of bundl s of
circular smooth muscle. Low (A–D) and high-magnification (E–H) H&E images, Masson’s Trichrome
images (I–L), and Pan-cytokeratin immunofluorescent i ages (M–P) for each of the three g oups and
the control (reproduced with permission from [73]).© 2015 The Korean Academy of M dical Sciences
SF is a natural polymer derived from Bombyx mori cocoons that holds promise for urethral tissue
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urethroplasty were functioning with no stricture all through the study duration (six months) [79].
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5. Future Directions: Hybrid and Smart Polymers
As it was previously shown, non-degradable materials did not meet the clinical performance
requirements. Despite the moderate success of degradable scaffolds in preclinical studies, the transition
from bench-to-bedside remains a challenge. There are, however, some novel approaches and materials
being investigated that might be able to meet the clinical performance requirements, alone or in
combination with some of the other systems presented here. Natural and synthetic materials can be
combined to produce hybrid biomaterials with desired properties for tissue engineering applications.
Such properties include mechanical strength, porosity and cell affinity to attract cells, biocompatibility,
and biodegradability for enabling replacement of ECM produced by resident cells. Current efforts
in biodegradable polymer synthesis are centered on determination of appropriate biomaterials and
synthesizing these materials with tailored properties for specific applications.
Another important advancement within the present decade is the emergence of a fourth generation
of “smart” biomi etic materials. Th se materials respond rev rsibly to t mperature, i nic strength,
pH, or light [87,88]. The responses of th se polym rs may include gelation, reversible adsorption on a
surface, collapse f a hydrogel, and alteration between hydrophilic and hydrophobic states. Moreover,
these materials can be loaded with signaling molecul s l ke ECM components and growth factors.
The delivery c uld be triggered using external stimuli (e.g. pH, temp rature, and light) or could be
done simultaneously as a result of programmable biodegradation of scaffolds [89]. S art biomaterials
have been investigated in drug delivery and medical devices application and more recently in tissue
engineering applications [90]. In a broader aspect, smart biomaterials can be designed by incorporating
peptide and/or protein into the polymer network, enabling the creation of a 3D scaffold for tissue
engineering application [91].
Thermo-responsive polymers are the largest class of smart polymers. These are characterized with
a reversibly alterable phase (or volume) transition that occurs in response to a change in temperature.
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The solubility of thermo-responsive polymers in aqueous solutions depend on the temperature. Above
lower critical solution temperature (LCST) polymer chains are precipitated making it hydrophobic,
and below LCST, polymer chains are completely hydrated, making it hydrophilic [92]. The most
investigated temperature-responsive polymer with LCST in water is the poly(N-isopropylacrylamide)
(PNIPAM). The LCST of PNIPAM was found to be around 32 ◦C, close to the human body temperature,
making the polymer particularly valuable for biological applications [93]. Therefore, by changing
the temperature of PNIPAM solution in water, its solubility can be changed from hydrophobic to
hydrophilic and vice versa. These characteristics found application in cell sheet engineering for
which cell attachment and detachment to or from material surfaces were needed. By avoiding
injurious enzymes for cell detachment, cell sheets with ECM proteins could be produced [92,94].
This method might be particularly useful for producing a three-layered urethra composed of different
cell monolayers (i.e. epithelial, fibroblast, and smooth muscle) [95]. In this direction, it has been shown
that viable urothelial cell sheets could be advantageously obtained by using a temperature-responsive
cell culture method [95].
Shape-memory polymers (SMPs) are another class of smart biomaterials. SMPs have been
experimented in various vascular and bone tissue engineering/regenerative medicine studies [96–98].
For that reason, it has been relevant to explore the concept in response to urinary stimuli. These
polymers exist in an original macroscopic shape, and temporarily stay in another shape until going
back to their original shape upon exposure to a stimulus, usually heat [99]. For urethral applications,
their capacity to stretch during erection and recoil during detumescence should be explored as well.
Smart acellular collagen–heparin scaffolds with growth factors (GFs) were shown to support bladder
tissue regeneration in a large animal model of diseased bladder [100]. Given the layered nature of
urethral tissue and the need to have different cell types in a peculiar spatial distribution close to
the native urethral tissue, stress-induced rolling membrane (SIRM) was shown to have the ability to
potentially be able to be studied for this purpose [101].
Another subset of smart polymers that has shown promise for engineering electrically active
tissues is the group of electroconductive polymers. Electroactive polyurethane polymers have shown
great potential in bladder tissue engineering applications, when the aim is to regenerate muscular
components and innervation [102–104]. Electroconductive polymers may be instrumental when
applying electrical or magnetic stimulation strategies for advanced maturation of the urethral tissue
engineered constructs [105]. Another potential method to enhance host–scaffold interaction is the
creation of smart scaffolds, which can controllably release trophic factors to optimize host reactions
toward the biomaterial [103].
Although several experiments have succeeded in regenerating the different urethral tissue
layers (i.e., epithelial and muscular layers) [13,55,106] not much attention has been paid to the
surrounding corpus spongiosum, which has been shown to be important for successful urethral surgical
repair [107–109]. Therefore, layered scaffolds can potentially have the ability to regenerate different
host tissues that resemble the normal histological architecture of the missing tissues. The incorporation
of a smooth muscle cell layer has been suggested to be necessary to obtain optimal cellular grafting
results [72].
In the future, advances in understanding the physical and chemical factors responsible for
urothelial and smooth muscle cell proliferation, migration, differentiation, and function may be
exploited in the development of smart biomaterials, in which biologically active agents are incorporated
into acellular natural or synthetic matrices. Not only interactions between urothelium and stroma,
but also bi-directional interactions between tissue-engineered grafts and the host tissue environment,
are important factors in achieving better outcomes in tissue remodeling. This concept has been
termed “dynamic reciprocity” [110]. With a further understanding of the biological complexity and
the physicochemical nature of native tissue, the appropriate design of new smart biomaterials will be
possible by active interdisciplinary collaboration, bringing together polymer chemists, biomaterials
scientists, tissue engineers, and clinicians (Figure 6).
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Figure 6. Desirable properties of polymeric scaffolds for urethral tissue engineering. These
design constraints appear to be fundamental to better resemble the physical, biological, and
structural properties of the native urethra and are expected to support an adequate recovery of
the urethral function.
6. Conclusions
The performance of the current treatments for long urethral strictures remains suboptimal due
to the shortage of tissue sources, the significant donor site morbidity, or the inability to completely
restore the structure and function of the host. While non-degradable polymers have not met the clinical
performance requirements because of the potential risk of migration, encrustation, and ultimate
narrowing, tissue-engineered solutions based on biodegradable polymers have emerged as potential
alternatives for successful recovery, and therefore function, of the urethral structure. Biological
scaffolds have shown utility to repair urethral defects, but they display relative mechanical inferiority
and their degradability cannot be easily adjusted. On the other hand, synthetic scaffolds have highly
controllable chemical, mechanical, and structural characteristics, but proper reproduction of the native
extracellular environment remains a challenge.
This suggests that combinations of natural and synthetic polymers could provide synergy with
a controllable degradation rate, mechanical compliance, and supportive of formation of different
tissue layers and vascularization. It is important to stress that a successful urethral scaffold should
maintain clinical performance (e.g. mechanical function) following implantation, and synchronize
with the preclinical performance requirements (e.g. degradation rate, ability to duplicate structure,
and integrate into the host). This can potentially be achieved by controlled degradation matching
regrowth of healthy tissues. Functional and smart polymeric scaffolds have the potential to better
mimic the native tissue and may help tissue engineered solutions to meet the pre-clinical and clinical
performance requirements in the future.
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